Neuroendocrine tumours are increasing in incidence and cause a variety of symptoms. The mammalian target of rapamycin (mTOR) pathway plays a key role in neuroendocrine tumour (NET) pathogenesis, leading to increased lipid synthesis, protein synthesis and cellular growth. Upregulation of this pathway is noted in both hereditary and sporadic NETs. This understanding has led to investigations of mTOR inhibitors as therapy for metastatic NETs. After promising preclinical findings, everolimus, an mTOR inhibitor, was trialled in the RADIANT-1−4 studies on patients with advanced, well differentiated NETs. RADIANT-3 and RADIANT-4 established the efficacy of everolimus in improving progressionfree survival (PFS) for metastatic NET of pancreatic, lung and gastrointestinal origin, leading to the US Food and Drug Administration (FDA) approval for its use in tumour control in those settings. Everolimus treatment is generally well tolerated; common adverse events include stomatitis, diarrhoea, rash and hyperglycaemia. Although discontinuation rates are low, many patients may require dose modification to successfully continue therapy. The combination of everolimus with somatostatin analogues (SSAs) (such as octreotide or pasireotide) or other targeted agents such as bevacizumab has not produced additional incremental benefit, and dual biologic therapy is not used widely. Ongoing trials are investigating everolimus compared with chemotherapy, optimal sequencing of therapy and combination of everolimus with radiotherapy. Future research should concentrate on identification of predictive biomarkers for benefit from mTOR therapy and include quality of life as a measure.
Introduction
Neuroendocrine tumours (NETs) are a heterogeneous group of malignancies arising from neuroendocrine cells that are scattered throughout the body. NETs most commonly arise from the gastrointestinal tract (particularly pancreas and small bowel), followed by lung, unknown primary, liver and thymus . Previously considered as a rare tumour, their incidence has increased markedly over the last 15 years [Hallet et al. 2015] . Increased incidence can be attributed to greater utilization of gastrointestinal (GI) investigations for vague or often unrelated symptoms (endoscopy and various modalities of greatly improved GI imaging), as well as greater clinician and patient awareness of the disease; increasing prevalence is due to the extended prognosis of many of these tumours, even with widespread metastatic disease.
NETs are challenging malignancies to diagnose and treat because of the marked variability in clinical presentation and course. Much progress has been made in the last 10 years in understanding the heterogeneity of NETs and developing appropriate clinical pathways for diagnosis, monitoring and therapy. NETs are usually classified by anatomical origin as well as histological grade based on the European Neuroendocrine Tumour Society (ENETS)/World Health Organization (WHO) 2010 classification (Table 1) [Klimstra et al. 2010] . The term gastroenteropancreatic NET (GEPNET) encompasses all tumours from the foregut, midgut and hindgut. However, certain subtypes of NET [particularly pancreatic NETs (pNET)] vary in terms of genetic mutations, clinical course and response to therapies, which is the basis for clinical trials being restricted to various predefined subgroups.
Metastatic NETs can cause symptoms from secretion of hormones (flushing, diarrhoea, hypoglycaemia, gastric ulcers from excess production of serotonin or specific hormones relating to cell of origin, for example, insulin from insulinoma, gastrin from gastrinoma) or from mass effect (pain, anorexia, weight loss, nausea, bowel obstruction). Until recently, treatment options in NETs were limited and consisted of somatostatin analogues (SSAs), which are highly effective in controlling hormonal secretory symptoms. Longacting formulations of SSA were subsequently shown to have an antiproliferative effect even in nonsecretory tumours [Caplin et al. 2014; Rinke et al. 2009 ]. Two other classes of therapy have been used for more than 20 years: interferon [di Bartolomeo et al. 1996; Faiss et al. 2003 ] and chemotherapy [Moertel et al. 1992] ; however, these have limited efficacy and a dearth of highquality evidence for use.
Understanding the molecular pathways underlying NET tumourogenesis and proliferation has been facilitated by the advent of highly sensitive deep sequencing and other molecular techniques. The identification of intracellular pathways amenable to targeting by specific 'biological agents' has been particularly successful. Targeting of the ubiquitous mammalian rapamycin (mTOR) pathway has been a story of rapid success in translational cancer therapeutics; NETs being a prime example of the successful implementation of this 'bench to bedside' approach.
The role of the mTOR pathway: the biological rationale for everolimus in treatment of neuroendocrine tumours mTOR is an intracellular protein kinase with critical functions related to cell-cycle control [Hashemolhosseini et al. 1998 ] and cell growth [Dufner and Thomas, 1999] . It is a serine/threonine kinase belonging to the phosphoinositide-3 kinase (PI3K) family that forms two complexes -mTOR complexes 1 and 2 (mTORC1, mTORC2). It receives much of its upstream inputs from tuberous sclerosis (TSC1/2) that transmits inputs from diverse pathways such as insulin-like growth factor 1 (IGF1), protein kinase B (Akt/PKB), extracellular-signal-regulated kinases 1 and 2 (ERK1/2), ribosomal s6 kinase 1 (RSK1) and the Wnt pathway ( Figure 1 ). It also receives inputs from TSC1/2-independent mechanisms such as Akt (via pras40) and AMPK. Downstream, mTORC1 upregulates protein synthesis, lipid synthesis and cellular metabolism, as well as downregulating autophagy. The role of mTORC2 is less well defined and the subject of ongoing research. For an extensive review of the mTOR pathway, readers are referred to Laplante and Sabatini [Laplante and Sabatini, 2012] .
As the name suggests, rapamycin has inhibitory effects on the mTOR pathway, and biosimilar drugs such as the oral agent everolimus (formerly known as RAD001) and the intravenous drug temsirolimus have been used for many years as a key component of the immunosuppressive regimen in organ-transplant recipients [Eisen et al. 2003; Webster et al. 2006 ]. Everolimus binds to the intracellular receptor FKBP-12 and inhibits the mTOR pathway. In significantly higher doses than its immunosuppressive effect, everolimus has shown anticancer activity in renal cell carcinoma [Motzer et al. 2008] and as a reverser of acquired resistance to aromatase inhibition in hormone-positive metastatic breast cancer [Baselga et al. 2012] .
Several key observations led to the investigation of mTOR inhibitors in NETs. Patients with TSC1/2 and neurofibromatosis (NF1), mediated by the TSC1/2 pathway, have an increased risk of NETs. TSC1/2 is intimately related to mTOR regulation and mTOR is constitutively activated in NF-1-deficient cells [Johannessen et al. 2005 ]. Whole-exome sequencing of initially 10 and then a further 58 pNETs demonstrated mutations in genes in the mTOR pathway in 14% of cases [Jiao et al. 2011] . A series of 99 GEPNETs reported a 70% rate of mutation in foregut NET and 53% in midgut NETs. Additionally, downregulation of the TSC2 gene was shown in 90 of 137 pNETs (67%), where pNET downregulation was seen in 56 of 137 (41%) [Missiaglia et al. 2010 ].
Treatment with both rapamcyin and RAD001 inhibited cell proliferation in various NET cellculture models [Missiaglia et al. 2010; Moreno et al. 2008; Zatelli et al. 2010 ]. Upregulation of mTOR and its downstream components (p-RPS6KB1, p-RPS6, or p-EIF4EBP1) in tissue from unexposed patients with resected/biopsied gastrointestinal and lung NETs was associated with shorter overall and progression-free survival (PFS) [Qian et al. 2013; Righi et al. 2010 ].
Based on the data above, a number of randomized phase II and III studies have been conducted to examine the clinical effect of everolimus in metastatic, inoperable GEPNETs. The major trials have been summarized in Table 2 .
The RADIANT trials
The RADIANT trials are a series of studies that have firmly embedded everolimus in the management of patients with metastatic NETs. The RADIANT-1 trial [Yao et al. 2010 ] was a single-arm phase II study of everolimus 10 mg daily in 160 patients with metastatic pNETs who had progressed after prior chemotherapy. The primary endpoint, response rate (RR), was reported at 9.6% in the stratum of 115 patients not being treated with octreotide with acceptable toxicity profiles. The median PFS was 9.7 months and overall survival (OS) was 24.9 months. A smaller cohort of 45 patients (Stratum 2) received everolimus and continued octreotide long-acting release (LAR) at the prestudy dose, with RR 4.4%, PFS 16.7 months and OS not reached at time of data cutoff.
RADIANT-1 formed the basis for proceeding to phase III randomized controlled trials to explore efficacy of everolimus in NET with carcinoid syndrome (RADIANT-2), pNET (RADIANT-3) and both lung and gastrointestinal NET (RADIANT-4). RADIANT-3 [Yao et al. 2011] RADIANT-2, [Pavel et al. 2011] commenced at the same time as RADIANT-3, was a phase III double-blinded randomized trial which investigated the use of everolimus in addition to SSA in 429 patients with advanced low-to-intermediate grade functional NETs originating in the small intestine (52%), lung (10%) and other GI primary sites (colon 6%, pancreas 6%, liver 4%, other 21%). Patients were randomized 1:1 to the combination of everolimus 10 mg daily plus octreotide LAR 30 mg every 28 days versus placebo plus octreotide LAR. PFS by central radiology review, the primary endpoint, was 16.4 versus 11.3 months respectively, with HR 0.77 (95% CI, 0.59-1.00; p = 0.026). As the significance boundary for the p value had been set at 0.0246 due to adjustment for two interim analyses, this result did not reach prespecified significance. On retrospective analysis, however, there was imbalance in the arms based on known prognostic indicators (the high proportion of patients with lung primary, performance status 1−2 and moderately differentiated disease in the everolimus group), as well as discrepancy between the central and local radiological review, reflecting a common issue of response assessment in NETs. Rates of toxicity were comparable with those noted in RADIANT-3.
RADIANT-4 [Yao et al. 2016 ] followed from the somewhat inconclusive RADIANT-2 results. The trial was designed to restrict enrolment to patients with either gastrointestinal or lung NETs without evidence of carcinoid syndrome. A total of 302 patients were randomized on a 2:1 basis to everolimus or placebo. Prior SSA treatment was allowed, but SSAs were not continued on study except to treat symptoms of carcinoid syndrome that emerged on trial. Crossover was not permitted until trial results were available. A total of 67% of patients had pathological grade 1 disease with the remainder having grade 2 disease according to the WHO 2010 classification. The most common primary tumour sites were lung (30%), ileum (24%) and rectum (13%). Patients were stratified by tumour site, prior SSA use and WHO performance status; baseline characteristics were well balanced. The primary endpoint, centrally assessed PFS, was met with a median of 11 months in the everolimus arm versus 3.9 months in the placebo arm; HR of 0.48 (0.35-0.67; p < 0.00001). Preliminary OS analyses indicated a trend toward improved OS (HR, 0.64; p = 0.037); formal data awaits maturation of the trial cohort.
Objective RR was 2% in the everolimus arm and 1% in placebo arm; disease stabilization was achieved in 81% of the everolimus arm compared with 64% with placebo. The adverse event profile was similar to RADIANT-2 and RADIANT-3, with treatment discontinuation rate 12% in the everolimus arm and a 16% incidence of pneumonitis (1% Grade 3; no Grade 4). An a priori analysis by primary tumour origin suggested consistent PFS benefit in patients with gastrointestinal primaries (HR, 0.56; 95% CI, 0.37-0.84) [Singh et al. 2016a ] and those with lung primary (HR, 0.50; 95% CI, 0.28-0.88) ].
Based on this data, everolimus has recently received US Food and Drug Administration (FDA) approval for the treatment of adult patients with progressive, well differentiated, nonfunctional, advanced NET of GI or lung origin. The abovementioned trials have caused much debate as to the optimal role of everolimus in the treatment paradigm, particularly in combination with SSA. In functional NETs, the use of SSA can ameliorate symptoms. However, the RADIANT-3 and -4 trials, as above, did not allow SSAs on enrolment. While patients on both arms of RADIANT-2 received SSAs, the change in statistical threshold for significance due to interim analyses meant that the p value of 0.026 was not deemed significant. The combination of SSA and everolimus, therefore, is known to be well tolerated, but its antineoplastic efficacy over either of the drugs alone, in either functional or nonfunctional NETs, is yet to be fully determined.
Everolimus in combination with new somatostatin analogues
Pasireotide is an SSA with greater affinity to the somatostatin receptors 1, 3 and particularly 5, in comparison with both octreotide and lanreotide that predominantly bind to somatostatin receptor 2. COOPERATE-2 [Kulke et al. 2015a ] was a phase II study in which 160 patients with advanced, progressive grade 1−2 pNET (56% with elevated chromogranin A or neuron-specific enolase (NSE)) were randomized to the combination of everolimus plus pasireotide versus everolimus alone. The results were reported in abstract form at ENETS 2015. PFS was not improved with HR 0.991 (95% CI, 0.64-1.54), although RR was significantly improved (20% versus 6%). Significantly higher rates of toxicity were noted with the combination, particularly hyperglycaemia (all grades 76% versus 27%) and diabetes mellitus (26% versus 7%). Results regarding symptom control have not yet been presented.
Everolimus in combination with other biological agents
CALGB 80701 [Kulke et al. 2015b ] was a randomized phase II trial comparing the combination of everolimus and the vascular endothelial growth factor (VEGF)-inhibitor bevacizumab (10 mg/kg twice per week) to everolimus alone in 150 patients with advanced Grade 1−2 pNET who had progressed in the prior 12 months. Patients in both arms, regardless of the functionality of the tumours, received concomitant octreotide at the standard institutional dosage. The patient population was roughly comparable with other major NET trials, with median age 59 years and 57% of patients having performance status 0. The primary endpoint, PFS, was marginally improved from 14 months to 16.7 months (HR, 0.80; p = 0.12); this was deemed statistically significant due to a predetermined p value cutoff of 0.15. The RR was also improved (31% versus 12%; p = 0.005). Grade 3-4 adverse events were reported in 81% of the combination arm and 49% of the monotherapy arm. Notably, Grade 3-4 hypertension occurred in 38% of bevacizumab arm compared with 8% of the monotherapy arm, with proteinuria (16% versus 1%), diarrhoea (11% versus 1%) and hypophosphataemia (10% versus 1%) all being more common in the combination arm; these are well known specific side effects of bevacizumab. Hyperglycaemia was not significantly different at 14% and 12%, respectively.
The results of the two trials above illustrate the amount that is still unknown about the use of everolimus. The increased RR observed in COOPERATE-2 failed to translate into an increased PFS. A study of single-agent pasireotide compared with octreotide in a phase III trial that did show improved PFS, but this was not the primary endpoint of the trial [Wolin et al. 2015] .
While the full publication of COOPERATE-2 is awaited, there is currently insufficient data to recommend the combination of everolimus and pasireotide in clinical practice.
The significant improvement in PFS seen in CALGB 80701 should also be seen as a preliminary finding. The RR of 31% is quite impressive in this cohort of patients, and points to the potential biological activity of this combination. The high alpha (type I error rate) of the trial design means that further confirmatory trials will be necessary to determine the true benefit of everolimus and bevacizumab in addition to octreotide. This route of investigation is further supported by a phase II single-arm trial of temsirolimus and bevacizumab in pNETs which reported a promising RR of 41% [Hobday et al. 2015] .
Quality of life
Quality of life (QOL) data were measured in RADIANT-4 using FACT-G; this was reported at two recent conferences. The time to deterioration in FACT-G was not significantly different in the two arms [Pavel et al. 2016a] ; disease progression was associated with worse FACT-G [Singh et al. 2016b] . No QOL data were collected in the other RADIANT trials. The only other data published on QOL in patients on everolimus comes from an expanded access programme involving 246 patients of which 50% had pNET. Patients with pNET experienced stable QOL during treatment, while patients with midgut NET reported a −13point change in QLQ-C30 from baseline, which was attributed mainly due to disease progression [Pavel et al. 2013] . The lack of extensive QOL data in NETS represents a gap in full understanding of best possible treatment in NET care. In an often indolent or slowly progressive disease like NETs, QOL may be an important factor in determining treatment options. It is imperative that further trials of everolimus in NETs include QOL. . Treatment is usually initiated at 10 mg daily, with dose reduction to 5 mg daily (level 1) then 5 mg every second day (level 2), in case of unmanageable toxicities. Dose reduction is required in clinical practice in a significant proportion of patients; 67% of patients treated with everolimus in RADIANT-4 underwent dose reductions or temporary treatment interruptions. In select poor-performance patients, 5 mg daily could be used as the initial dose with uptitration to 10 mg daily if treatment is well tolerated. Regular tumour measurements, with computed tomography or magnetic resonance imaging at approximately 3-monthly intervals is recommended, as per the RADIANT trials, as well as monitoring of serum chromogranin A/urinary 5-HIAA according to institutional practice.
Future directions
Everolimus has been firmly established as a viable and effective treatment option in NETs, moving from the pNET population to now encompass patients with metastatic NET of any origin, since the recent publication of the RADIANT-4 trial. However, many questions remain, including understanding of the development of resistance to mTOR inhibition and optimal partnering with other antiproliferative agents, as well as sequencing strategies. While multiple candidate biomarkers have been explored to predict efficacy of everolimus, no effective and reproducible biomarker has been identified. A phase II trial of temsirolimus identified higher baseline plasma mTOR levels as a predictor of treatment response, but this is yet to be shown as useful in clinical monitoring.
Currently, everolimus is approved in the treatment of nonfunctional GI NETs based on the results of the RADIANT-4 clinical trial. Based on the ambiguous results of the RADIANT-2 trial, it is unclear as to the effect of everolimus in functional patients. Recent studies [Caplin et al. 2014; Rinke et al. 2009 ] have confirmed the antiproliferative effect of SSAs which may have muted the effect of everolimus in the RADIANT-2 trial, in addition to the problems with study design (imbalance between the arms, discrepancy in response determination in central versus local review). Although everolimus is known to be beneficial in certain specific hormonal syndromes such as insulinoma [Kulke et al. 2009 ], its use in functional GI NETs remains unclear. There appears to be little evidence pointing towards a clinical discrepancy between functional and nonfunctional GI NETs [Wang et al. 2011] .
Conclusion
The establishment of everolimus as an oral, effective treatment option in NETs is an exemplar of translational medicine. Further research will investigate the value of combining everolimus with other therapies targeting intersecting cellular pathways and the important question of optimally sequencing NET therapies. Deeper understanding of the molecular landscape of the heterogeneous entity of NETs will drive research into diagnostic and therapeutic options and help achieve prolonged survival and improved QOL for NET patients.
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